- Novo Nordisk is acquiring two U.S. biotechs, Calibrium LLC and MB2 LLC, in an effort to expand its pipeline of diabetes-related drugs.
- In addition, Novo just annouced plans to invest $2 billion to increase manufacturing capacity in the U.S. and Denmark.
- The closing of the transaction with Calibrium and MB2 is expected in Q3 2015.
Novo is in a strong position to expand manufacturing capacity and make targeted acqusitions. Moreover, its expansion bodes particularly well for the jobs market in Clayton, NC, where the company will create 700 new production and engineering jobs.
In addition, a new production facility in Denmark will add 100 jobs for tableting and packaging of semaglutide and other future oral products. This is definitely a vote of confidence on Novo's part—and relfects a strong and growing pipeline.